University of Michigan

Other

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Cory Hogaboam

Steven L Kunkel

Nicholas W Lukacs

Vladislav A Dolgachev

Sem H Phan

Raj K Puri

Robert M Strieter

Kenneth J Simpson

Cynthia L Bone-Larson

Lisa M Colletti

Claudia Jakubzick

Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.

Antibody targeting stem cell factor

Stem cell factor inhibitor

Methods and compositions for the treatment of fibrosing diseases are described. More specifically, the invention demonstrates that inhibiting or otherwise decreasing the activity of CCL21 either alone or in combination with CCL19 will be effective in reducing the presence of fibrotic lesions and ameliorating the symptoms of fibrosing disorders.

Methods for treating pulmonary fibrosis

The invention provides uses and methods for alleviating respiratory tract symptoms of allergy, asthma, and of viral, bacterial, fungal and parasitic infections by shifting inappropriate TH2 responses to TH1 responses by administering IL-13 receptor-targeted immunotoxins to the respiratory tract.

Chimeric molecule for the treatment of th2-like cytokine mediated disorders

Disclosed is the surprising discovery that CXC chemokines function to induce rapid hepatocyte proliferation and liver regeneration after injury. The invention thus provides a range of compositions and methods for use in treating liver injury, including those suitable for treating acetaminophen overdose outside the therapeutic window for N-acetyl-cysteine treatment, and those that limit the hepatotoxic side-effects of gene therapy regimens.

Treatment of liver disease and injury with CXC chemokines

Growing community of inventors

Ann Arbor, MI, United States of America

Cory Hogaboam